Bionomics

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Retrieved on: 
Thursday, February 22, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.
  • Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics will be providing an update on the Company’s leading asset, BNC210, a Phase 3 ready, first- and best-in-class α7 nicotinic receptor negative allosteric modulator in development for the treatment of social anxiety disorder and post-traumatic stress disorder.
  • For those interested in meeting Bionomics’ management during the conference, please request a meeting through the conference portal or contact the Company’s Investor Relations.
  • FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics to Present at Biotech Showcase™ 2024

Retrieved on: 
Friday, January 5, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the Biotech Showcase™ 2024 taking place January 8-10 in San Francisco, California.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the Biotech Showcase™ 2024 taking place January 8-10 in San Francisco, California.
  • Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics will be providing an update on the Company’s leading asset, BNC210, a Phase 3 ready α7 nicotinic receptor negative allosteric modulator with the potential to be first- and best-in-class in social anxiety disorder and post-traumatic stress disorder.
  • Location: Hilton San Francisco – Union Square, Yosemite A
    Company’s management will be available for one-on-one meetings with registered investors and potential partners.
  • In addition, Bionomics will host one-on-one meetings in San Francisco during JP Morgan week.

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder

Retrieved on: 
Monday, October 16, 2023

“We are grateful for FDA’s support and guidance and very pleased to reach an agreement on key elements of Phase 3 design and other nonclinical components required for registration”, said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics.

Key Points: 
  • “We are grateful for FDA’s support and guidance and very pleased to reach an agreement on key elements of Phase 3 design and other nonclinical components required for registration”, said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics.
  • “The FDA meeting outcomes provide external and independent validation of our position on the strength and Phase 3-enabling nature of the PREVAIL dataset.
  • BNC210’s unique clinical profile seen in multiple anxiety disorders including SAD, Generalized Anxiety Disorder and in a panic model, was recently significantly enhanced by the positive results in Post-Traumatic Stress Disorder.
  • The Company anticipates beginning the Phase 3 program in Q1’24.

Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)

Retrieved on: 
Thursday, September 28, 2023

Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD.

Key Points: 
  • Company plans to engage with the U.S. Food and Drug Administration (FDA) to discuss the registrational path for BNC210 in PTSD.
  • “We are excited about the results of the ATTUNE trial that delivered a positive dataset with treatment effects considerably higher than currently approved therapies.
  • Despite the clinical heterogeneity of PTSD, the results of ATTUNE demonstrated broad benefits with BNC210 across a number of symptoms.
  • The company will discuss the topline ATTUNE study results on the webcast today at 8:00am EST and is planning to advance BNC210 for the treatment of PTSD into registrational studies.

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Retrieved on: 
Thursday, September 14, 2023

MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.

Key Points: 
  • MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.
  • Under the 2014 exclusive Research Collaboration and License Agreement, MSD funds all research and clinical development, and worldwide commercialization of any resulting products.
  • This collaboration generated payments of $20M upfront and $10M for a Phase 1 milestone.
  • Bionomics is eligible to receive up to $465M in additional milestone payments for certain development and commercial milestones plus royalties on net sales of licensed drugs.

Bionomics Completes Last Patient Last Visit in the Phase 2b ATTUNE Study for Post-Traumatic Stress Disorder (PTSD) and Confirms Expected 2023 Milestones with its Lead Asset BNC210

Retrieved on: 
Wednesday, August 23, 2023

“I would like to thank study participants, their families, our clinical site investigators and their staff and our clinical team for their contributions towards achieving completion of the ATTUNE study.

Key Points: 
  • “I would like to thank study participants, their families, our clinical site investigators and their staff and our clinical team for their contributions towards achieving completion of the ATTUNE study.
  • The EoPh2 meeting to discuss advancing BNC210 into Phase 3 development as an acute treatment for SAD has been scheduled for mid-September 2023.
  • Additionally, Bionomics is scheduled to delist from the Official List of the Australian Securities Exchange on 28 August 2023.
  • The Company will remain an Australian incorporated company and will maintain its listing of ADSs on Nasdaq under the trading symbol ‘BNOX’.

Quarterly Activities and Cashflow Report

Retrieved on: 
Monday, July 31, 2023

On 28 April 2023, Bionomics released its Appendix 4C – Quarterly Cashflow Report for the quarter ended 31 March 2023.

Key Points: 
  • On 28 April 2023, Bionomics released its Appendix 4C – Quarterly Cashflow Report for the quarter ended 31 March 2023.
  • Bionomics may determine to sell some, all, or none of the ADSs under the ATM Program and may terminate the ATM Program at its discretion.
  • Start-up activities for a planned Phase 3 trial of BNC210 in SAD are underway.
  • A copy of the full release, including a copy of the ASX Appendix 4C Cashflow Report can be found on the Company's website.

Bionomics Announces Intention to Delist from the Australian Securities Exchange (ASX)

Retrieved on: 
Tuesday, July 25, 2023

“Bionomics is approaching several very important value-inflection milestones for our late-stage clinical development program with BNC210, a first and best-in class α7 nicotinic receptor negative allosteric modulator under evaluation in patients with Social Anxiety Disorder (SAD) and Post-Traumatic Stress Syndrome (PTSD), in the coming quarters,” said Spyros Papapetropoulos, M.D.

Key Points: 
  • “Bionomics is approaching several very important value-inflection milestones for our late-stage clinical development program with BNC210, a first and best-in class α7 nicotinic receptor negative allosteric modulator under evaluation in patients with Social Anxiety Disorder (SAD) and Post-Traumatic Stress Syndrome (PTSD), in the coming quarters,” said Spyros Papapetropoulos, M.D.
  • Ph.D., Bionomics’ President and CEO; “As we continue our transformation to a U.S.-focused organization, we would like to deepen our engagement with the broadest range of potential investors and maximize Bionomics’ access to capital and financing opportunities while reducing costs and compliance obligations associated with a dual listing.
  • All information will be made available at https://ir.bionomics.com.au/ .
  • FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Retrieved on: 
Monday, July 3, 2023

Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.

Key Points: 
  • Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.
  • Mr. Fisher commented, “On behalf of the Board, I would like to express my excitement for Bionomics’ prospects and confidence in the team being assembled.
  • “Collectively, Tim, Julie, and Atul bring over 50+ years of experience in the biopharma sector, and diverse expertise in developing and commercializing drug products.
  • His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice.

Bionomics to Present at Upcoming June Investor Conferences

Retrieved on: 
Thursday, June 15, 2023

ADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that it will present at the following upcoming investor conferences in June:

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need, today announced that it will present at the following upcoming investor conferences in June:
    Presentation format: Panel discussion titled “Mental Health, More Critical Than Ever”
    Presentation date and time: On demand beginning at 7:00 am ET on June 26, 2023
    Links to access webcasts for select events, when available, will be posted to Bionomics’ website on the Events page of the Investors section.
  • FOR FURTHER INFORMATION PLEASE CONTACT: